Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological documentation of adenocarcinoma of the colon or rectum;~* Subject must have received at least oxaliplatin-, and irinotecan-based regimens with bevacizumab and with, cetuximab or panitumumab if KRAS wildtype and are refractory to irinotecan;~* Subject has measurable disease by radiographic techniques (computerized tomography \[CT\] or magnetic resonance imaging \[MRI\]);~* Subjects with a history of brain metastasis are eligible for the study as long as they meet all the following criteria: their brain metastases have been treated, they have no evidence of progression or hemorrhage after treatment, have been off dexamethasone for 4 weeks prior to first study drug administration, and have no ongoing requirement for dexamethasone or anti-epileptic drugs;~* Life expectancy of at least 12 weeks~* Subject's Eastern Cooperative Group (ECOG) performance status is 0 or 1;~* Adequate organ function~* Fertile subjects must use effective contraception during the course of the study and for 30 days following withdrawal from the study;~Exclusion Criteria:~* Clinically significant cardiovascular disease;~* Unresolved toxicity higher attributed to any prior therapy/procedure excluding alopecia, hypothyroidism and oxaliplatin- induced neurotoxicity ≤ Grade 2 for at least 14 days;~* Evidence or history of tendency or predisposition to active bleeding. Any hemorrhage or bleeding event of Grade 3 or higher within 4 weeks of start of study medication;~* Symptoms or signs of active brain metastases;~* History of an allergic reaction or intolerance to irinotecan~* Hepatic encephalopathy~* Cholangitis that required treatment or intervention within 4 weeks of study enrollment~* Concurrent anticancer therapy or any cytotoxic therapy within 1 month prior to Day 1. Corticosteroid therapy is not allowed except on dosing days;~* Subject has previously received regorafenib;~* Clear contraindication for systemic corticosteroids (diabetes mellitus is not per se a clear contraindication);~* Severe hypoalbuminemia (albumin \< 3.0 g/dL);~* Subjects who are pregnant or lactating or who are planning to become pregnant during the course of the study are excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RRx-001 followed by irinotecan (Type: EXPERIMENTAL): Once-weekly intravenous RRx-001 at a dose of 4 mg on Days 1, 8, 15, and 22 of a 4-week cycle. On progression and if eligible, patients will receive irinotecan (with or without bevacizumab)
- Regorafenib followed by irinotecan (Type: ACTIVE_COMPARATOR): Regorafenib daily on Days 1- 21 of a 4-week cycle. On progression and if eligible, patients will receive irinotecan (with or without bevacizumab)

Based on this trial design, predict the completion outcome and termination type (if applicable).